NEUBASE THERAPEUTICS INC (NBSE) Stock Analyst Ratings
USA - NASDAQ:NBSE - US64132K2015 - Common Stock
0.378 USD
-0.01 (-3.2%)
0.42 USD
+0.04 (+11.11%)
ChartMill assigns a Buy % Consensus number of 43% to NBSE. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 142.8. This target is 37677.78% above the current price.
NBSE was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about NBSE.
In the previous month the buy percentage consensus was at a similar level.
NBSE was analyzed by 6 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-10-21 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2022-10-18 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2022-10-17 | Chardan Capital | Downgrade | Buy -> Neutral |
| 2022-08-12 | Chardan Capital | Maintains | Buy |
| 2022-05-31 | HC Wainwright & Co. | Maintains | Buy |
| 2022-05-13 | Chardan Capital | Maintains | Buy |
| 2021-06-01 | HC Wainwright & Co. | Maintains | Buy |
| 2021-02-12 | HC Wainwright & Co. | Maintains | Buy |
NEUBASE THERAPEUTICS INC / NBSE FAQ
What is the average price target for NEUBASE THERAPEUTICS INC (NBSE) stock?
6 analysts have analysed NBSE and the average price target is 142.8 USD. This implies a price increase of 37677.78% is expected in the next year compared to the current price of 0.378.
Can you provide the consensus rating for NEUBASE THERAPEUTICS INC stock?
The consensus rating for NEUBASE THERAPEUTICS INC (NBSE) is 43.3333 / 100 . This indicates that analysts generally have a neutral outlook on the stock.
Can you provide the analyst count for NEUBASE THERAPEUTICS INC stock?
The number of analysts covering NEUBASE THERAPEUTICS INC (NBSE) is 6.